#BEGIN_DRUGCARD DB00156

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
72-19-5

# ChEBI_ID:
16857

# Chemical_Formula:
C4H9NO3

# Chemical_IUPAC_Name:
(2S,3R)-2-amino-3-hydroxybutanoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Dietary supplement
Essential Amino Acids
Micronutrient

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.94

# Experimental_Logs:
-0.09

# Experimental_Water_Solubility:
9.7E+004 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Threonine

# HET_ID:
THR

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1

# InChI_Key:
InChIKey=AYFVYJQAPQTCCC-GBXIJSLDSA-N

# Indication:
L-Threonine makes up collagen, elastin, and enamel protein. It aids proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation.

# KEGG_Compound_ID:
C00188

# KEGG_Drug_ID:
D00041

# LIMS_Drug_ID:
156

# Mechanism_Of_Action:
L-Threonine is a precursor to the amino acids glycine and serine. It acts as a lipotropic in controlling fat build-up in the liver. May help combat mental illness and may be very useful in indigestion and intestinal malfunctions. Also, threonine prevents excessive liver fat. Nutrients are more readily absorbed when threonine is present.

# Melting_Point:
256 dec °C

# Molecular_Weight_Avg:
119.1192

# Molecular_Weight_Mono:
119.058243159

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1NYR

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451673

# Pharmacology:
L-Threonine is an essential amino acid that helps to maintain the proper protein balance in the body. It is important for the formation of collagen, elastin, and tooth enamel, and aids liver and lipotropic function when combined with aspartic acid and methionine.

# Predicted_LogP_Hydrophobicity:
-3

# Predicted_LogS:
0.6

# Predicted_Water_Solubility:
4.77e+02 g/l

# Primary_Accession_No:
DB00156

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
6288

# PubChem_Substance_ID:
46506798

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00057

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@@H](O)[C@H](N)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(S)-Threonine
2-Amino-3-hydroxybutyric acid
L-(-)-Threonine
Threonin
Threonine
[R-(R*,S*)]-2-Amino-3-hydroxybutanoic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:08 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/L-Threonine

# pKa_Isoelectric_Point:
5.60

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
THNSL1

# Drug_Target_1_GenBank_ID_Gene:
BC035132

# Drug_Target_1_GenBank_ID_Protein:
23243453

# Drug_Target_1_GeneCard_ID:
THNSL1

# Drug_Target_1_Gene_Name:
THNSL1

# Drug_Target_1_Gene_Sequence:
>2232 bp
ATGCTCCACTTTAACCGATGTCATCATCTGAAAAAGATAACACAGAAATGTTTTTCTAGT
ATACATGTTAAAACGGATAAACATGCACAGCGATTTCTTTCAAGAACCTTTGCACTTGCG
GAATTGAGGAAGTCATGGTATTCAACCCACTCTCTTGTTGGAGACAAAAATATTATCCTG
ATGGGACCTCCTGGTGCTGGGAAAACAACAGTAGGCAGAATAATAGGTCAGAAACTAGGT
TGTTGTGTCATAGATGTGGATGATGATATCCTTGAAAAAAACTGGAATATGAGTGTGTCT
GAAAAATTACAGGATGTTGGTAATGAGCAATTTTTAGAAGAGGAAGGAAAAGCTGTGTTA
AACTTCTCTGCATCTGGAAGTGTGATTTCCCTTACTGGGTCCAATCCAATGCATGATGCT
AGCATGTGGCATCTGAAGAAAAATGGAATAATTGTATACCTGGATGTACCTCTACTAGAT
CTAATTTGTCGTCTAAAATTAATGAAGACAGATAGGATTGTAGGTCAGAATTCTGGAACA
TCTATGAAAGACTTACTTAAATTTAGAAGACAGTATTATAAGAAGTGGTATGATGCTCGT
GTTTTCTGTGAAAGTGGGGCTTCCCCAGAGGAGGTAGCTGACAAAGTGCTGAATGCAATT
AAAAGATACCAAGATGTGGACTCGGAAACATTCATTTCAACAAGACACGTTTGGCCTGAA
GACTGTGAACAGAAGGTTTCAGCAAAATTCTTTAGTGAAGCTGTAATTGAGGGGTTGGCT
TCTGATGGTGGCCTCTTTGTTCCTGCAAAGGAGTTTCCAAAATTAAGCTGCGGGGAGTGG
AAAAGCCTAGTAGGAGCAACCTACGTAGAAAGAGCACAGATACTGTTGGAAAGATGTATC
CATCCTGCAGACATACCTGCTGCCAGGTTGGGAGAAATGATTGAAACTGCTTATGGGGAA
AACTTTGCCTGCTCAAAAATTGCTCCTGTCAGGCACCTTTCAGGCAACCAGTTCATCCTG
GAGTTGTTTCATGGACCAACAGGATCATTTAAAGATTTGTCTTTACAGCTTATGCCTCAT
ATTTTTGCACACTGTATCCCACCAAGTTGCAATTATATGATACTTGTAGCTACTTCAGGA
GACACAGGGAGTGCAGTCTTAAATGGTTTTAGTCGTCTAAATAAGAATGATAAGCAAAGG
ATAGCTGTGGTTGCATTTTTTCCTGAGAATGGAGTAAGTGATTTTCAAAAAGCACAAATA
ATTGGCAGTCAGAGAGAAAATGGATGGGCAGTGGGTGTTGAGTCAGATTTTGATTTTTGC
CAGACAGCTATAAAAAGAATTTTTAATGATTCTGATTTTACTGGCTTTCTTACTGTGGAA
TATGGAACAATCTTAAGTTCGGCTAACTCCATAAACTGGGGCCGACTACTTCCGCAGGTA
GTTTATCATGCTTCCGCATATCTTGATCTTGTTAGTCAAGGATTTATTTCTTTTGGAAGC
CCAGTCGATGTCTGTATTCCCACAGGAAACTTTGGTAACATTTTAGCAGCAGTGTATGCC
AAAATGATGGGAATCCCGATTCGAAAATTTATCTGTGCCTCTAATCAGAACCATGTTTTG
ACTGATTTTATAAAAACAGGACATTATGATCTAAGGGAAAGAAAACTAGCACAAACCTTT
TCACCGTCAATAGATATTCTCAAATCTTCAAACCTAGAACGACATTTACACTTGATGGCT
AATAAAGATGGACAGCTAATGACAGAATTATTTAATCGATTAGAAAGTCAGCATCATTTC
CAGATAGAAAAGGCTCTAGTTGAGAAACTTCAGCAGGATTTTGTAGCTGACTGGTGCTCT
GAGGGAGAGTGCCTAGCAGCTATTAACTCCACCTATAATACTTCAGGGTATATTTTGGAT
CCACACACTGCTGTTGCAAAAGTGGTTGCAGATAGGGTGCAAGACAAAACTTGCCCTGTG
ATTATCTCATCTACAGCCCATTACTCAAAGTTTGCACCTGCTATCATGCAGGCTTTAAAG
ATTAAAGAAATCAATGAGACTTCATCAAGTCAGCTCTATTTGCTGGGTTCATACAATGCA
TTACCTCCACTGCGTGAGGCTTTATTAGAGAGAACAAAACAGCAAGAGAAGATGGAGTAC
CAGGTCTGTGCAGCTGATATGAATGTCTTGAAGAGTCATGTGGAACAACTTGTCCAAAAT
CAATTCATATGA

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
HGNC:26160

# Drug_Target_1_HPRD_ID:
07974

# Drug_Target_1_ID:
534

# Drug_Target_1_Locus:
10p12.1

# Drug_Target_1_Molecular_Weight:
83071

# Drug_Target_1_Name:
Threonine synthase-like 1

# Drug_Target_1_Number_of_Residues:
743

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00291	PALP
PF01202	SKI

# Drug_Target_1_Protein_Sequence:
>Threonine synthase-like 1
MLHFNRCHHLKKITQKCFSSIHVKTDKHAQRFLSRTFALAELRKSWYSTHSLVGDKNIIL
MGPPGAGKTTVGRIIGQKLGCCVIDVDDDILEKTWNMSVSEKLQDVGNEQFLEEEGKAVL
NFSASGSVISLTGSNPMHDASMWHLKKNGIIVYLDVPLLDLICRLKLMKTDRIVGQNSGT
SMKDLLKFRRQYYKKWYDARVFCESGASPEEVADKVLNAIKRYQDVDSETFISTRHVWPE
DCEQKVSAKFFSEAVIEGLASDGGLFVPAKEFPKLSCGEWKSLVGATYVERAQILLERCI
HPADIPAARLGEMIETAYGENFACSKIAPVRHLSGNQFILELFHGPTGSFKDLSLQLMPH
IFAHCIPPSCNYMILVATSGDTGSAVLNGFSRLNKNDKQRIAVVAFFPENGVSDFQKAQI
IGSQRENGWAVGVESDFDFCQTAIKRIFNDSDFTGFLTVEYGTILSSANSINWGRLLPQV
VYHASAYLDLVSQGFISFGSPVDVCIPTGNFGNILAAVYAKMMGIPIRKFICASNQNHVL
TDFIKTGHYDLRERKLAQTFSPSIDILKSSNLERHLHLMANKDGQLMTELFNRLESQHHF
QIEKALVEKLQQDFVADWCSEGECLAAINSTYNTSGYILDPHTAVAKVVADRVQDKTCPV
IISSTAHYSKFAPAIMQALKIKEINETSSSQLYLLGSYNALPPLHEALLERTKQQEKMEY
QVCAADMNVLKSHVEQLVQNQFI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q8IYQ7

# Drug_Target_1_SwissProt_Name:
THNS1_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
7.13

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
12875846	Torres-Larios A, Sankaranarayanan R, Rees B, Dock-Bregeon AC, Moras D: Conformational movements and cooperativity upon amino acid, ATP and tRNA binding in threonyl-tRNA synthetase. J Mol Biol. 2003 Aug 1;331(1):201-11.
15507440	Ruan B, Bovee ML, Sacher M, Stathopoulos C, Poralla K, Francklyn CS, Soll D: A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases. J Biol Chem. 2005 Jan 7;280(1):571-7. Epub 2004 Oct 26.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9493271	Cusack S, Yaremchuk A, Krikliviy I, Tukalo M: tRNA(Pro) anticodon recognition by Thermus thermophilus prolyl-tRNA synthetase. Structure. 1998 Jan 15;6(1):101-8.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
TARS

# Drug_Target_2_GenBank_ID_Gene:
M63180

# Drug_Target_2_GenBank_ID_Protein:
1464742

# Drug_Target_2_GeneCard_ID:
TARS

# Drug_Target_2_Gene_Name:
TARS

# Drug_Target_2_Gene_Sequence:
>2139 bp
ATGGGAGGCGAGGAGAAGCCGATTGGTGCTGGTGAAGAGAAGCAAAAGGAAGGAGGCAAA
AAGAAGAACAAAGAAGGATCTGGAGATGGAGGTCGAGCTGAGTTGAATCCTTGGCCTGAA
TATATTTACACACGTCTTGAGATGTATAATATACTAAAAGCAGAACATGATTCCATTCTG
GCAGAAAAGGCAGAAAAAGATAGCAAGCCAATTAAAGTCACTTTGCCTGATGGTAAACAG
GTTGATGCGGAATCTTGGAAAACTACACCATATCAAATTGCCTGTGGAATTAGTCAAGGC
CTGGCCGACAACACCGTTATTGCTAAAGTAAATAATGTTGTGTGGGACCTGGACCGCCCT
CTGGAAGAAGATTGTACCTTGGAGCTTCTCAAGTTTGAGGATGAGGAAGCTCAGGCAGTG
TATTGGCACTCTAGTGCTCACATAATGGGTGAAGGCATGGAAAGAGTCTATGGTGGATGT
TTATGCTACGGTCCGCCAATAGAAAATGGATTCTATTATGACATGTACCTCGAAGAAGGG
GGTGTGTCTAGCAATGATTTCTCTTCTCTGGAGGCTTTGTGTAAGAAAATCATTAAAGAA
AAACAAGCTTTTGAAAGACTGGAAGTTAAGAAAGAAACTTTACTGGCAATGTTTAAGTAC
AACAAGTTCAAATGCCGGATATTGAATGAAAAGGTGAATACTCCAACTACCACAGTCTAT
AGATGTGGCCCTTTGATAGATCTCTGCCGGGGTCCTCATGTTAGACACACGGGCAAAATT
AAGGCTTTAAAAATACACAAAAATTCCTCCACGTACTGGGAAGGCAAAGCAGATATGGAG
ACTCTCCAGAGAATTTATGGCATTTCATTCCCAGATCCTAAAATGTTGAAAGAGTGGGAG
AAGTTCCAAGAGGAAGCTAAAAACCGAGATCATAGGAAAATTGGCAGGGACCAAGAACTA
TATTTCTTTCATGAACTCAGCCCTGGAAGTTGCTTTTTTCTGCCAAAAGGAGTCTATATT
TATAATGCACTTATTGAATTCATTAGGAGCGAATATAGGAAAAGAGGATTCCAGGAGGTA
GTCACCCCAAACATCTTCAACAGCCGACTCTGGATGACCTCGGGCCACTGGCAGCACTAC
AGCGAGAACATGTTCTCCTTTGAGGTGGAGAAGGAGCTGTTTGCCCTGAAACCCATGAAC
TGCCCAGGACACTCCCTTATGTTTGATCATCGGCCAAGGTCCTGGCGAGAACTGCCTCTG
CGGCTAGCTGATTTTGGGGGTCTTCATAGGAACGAGCTGTCTGGAGCACTCACAGGACTC
ACCCGGGTACGAAGATTCCAACAGGATGATGCTCACATATTCTGTGCCATGGAGCAGATT
GAAGATGAAATAAAAGGTTGTTTGGATTTTCTACGTACGGTATATAGCGTATTTGGATTT
TCTTTTAAACTAAACCTTTCTACTCGCCCGGAAAAATTCCTTGGAGATATCGAAGTATGG
GATCAAGCTGAGAAACAACTTGAAAACAGTCTGAATGAATTTGGTGAAAAGTGGGAGTTA
AACTCTGGAGATGGAGCTTTCTATGGCCCAAAGATTGACATACAGATTAAAGATGCGATT
GGGCGGTACCACCAGTGTGCAACCATCCAGCTGGATTTCCAGTTGCCCATCAGATTTAAT
CTTACTTATGTAAGCCATGATGGTGAGGATAAGAAAAGGCCAGTGATTGTTCATCGAGCC
ATCTTGGGATCAGTGGAAAGAATGATTGCTATCCTCACAGAAAACTATGGGGGCAAATTG
GCCCCCTTTTGGCTGTCCCCTCGCCAGGTAATGGTAGTTCCAGTGGGACCAACCTGTGAT
GAATATGCCCAAAACGTACGACAACAATTCCACGATGCCAAATTCATGGCAGACATTGAT
CTGGATCCAGGCTGTACATTGAATAAAAAGATTCGAAATGCACAGTTAGCACAGTATAAC
TTCATTTTAGTTGTTGGTGAAAAAGAGAAAATCACTGGCACTGTTAATATCCGCACAAGA
GACAATAAGGTCCACGGGGAACGCACCATTTCTGAAACTATCGAGCGGCTACAGCAGCTC
AAAGAGTTCCGCAGCAAACAGGCAGAAGAAGAATTTTAA

# Drug_Target_2_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_2_General_References:
2033077	Cruzen ME, Arfin SM: Nucleotide and deduced amino acid sequence of human threonyl-tRNA synthetase reveals extensive homology to the Escherichia coli and yeast enzymes. J Biol Chem. 1991 May 25;266(15):9919-23.

# Drug_Target_2_HGNC_ID:
HGNC:11572

# Drug_Target_2_HPRD_ID:
01762

# Drug_Target_2_ID:
261

# Drug_Target_2_Locus:
5p13.2

# Drug_Target_2_Molecular_Weight:
83436

# Drug_Target_2_Name:
Threonyl-tRNA synthetase, cytoplasmic

# Drug_Target_2_Number_of_Residues:
723

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00587	tRNA-synt_2b
PF02824	TGS
PF03129	HGTP_anticodon
PF07973	tRNA_SAD

# Drug_Target_2_Protein_Sequence:
>Threonyl-tRNA synthetase, cytoplasmic
MFEEKASSPSGKMGGEEKPIGAGEEKQKEGGKKKNKEGSGDGGRAELNPWPEYIYTRLEM
YNILKAEHDSILAEKAEKDSKPIKVTLPDGKQVDAESWKTTPYQIACGISQGLADNTVIA
KVNNVVWDLDRPLEEDCTLELLKFEDEEAQAVYWHSSAHIMGEAMERVYGGCLCYGPPIE
NGFYYDMYLEEGGVSSNDFSSLEALCKKIIKEKQAFERLEVKKETLLAMFKYNKFKCRIL
NEKVNTPTTTVYRCGPLIDLCRGPHVRHTGKIKALKIHKNSSTYWEGKADMETLQRIYGI
SFPDPKMLKEWEKFQEEAKNRDHRKIGRDQELYFFHELSPGSCFFLPKGAYIYNALIEFI
RSEYRKRGFQEVVTPNIFNSRLWMTSGHWQHYSENMFSFEVEKELFALKPMNCPGHCLMF
DHRPRSWRELPLRLADFGVLHRNELSGALTGLTRVRRFQQDDAHIFCAMEQIEDEIKGCL
DFLRTVYSVFGFSFKLNLSTRPEKFLGDIEVWDQAEKQLENSLNEFGEKWELNSGDGAFY
GPKIDIQIKDAIGRYHQCATIQLDFQLPIRFNLTYVSHDGDDKKRPVIVHRAILGSVERM
IAILTENYGGKWPFWLSPRQVMVVPVGPTCDEYAQKVRQQFHDAKFMADIDLDPGCTLNK
KIRNAQLAQYNFILVVGEKEKISGTVNIRTRDNKVHGERTISETIERLQQLKEFRSKQAE
EEF

# Drug_Target_2_Reaction:
ATP + L-threonine + tRNAThr = AMP + diphosphate + L-threonyl-tRNAThr

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P26639

# Drug_Target_2_SwissProt_Name:
SYTC_HUMAN

# Drug_Target_2_Synonyms:
EC 6.1.1.3
ThrRS
Threonine--tRNA ligase

# Drug_Target_2_Theoretical_pI:
6.64

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Mitochondrion

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17644600	Caillet J, Graffe M, Eyermann F, Romby P, Springer M: Mutations in residues involved in zinc binding in the catalytic site of Escherichia coli threonyl-tRNA synthetase confer a dominant lethal phenotype. J Bacteriol. 2007 Oct;189(19):6839-48. Epub 2007 Jul 20.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
TARS2

# Drug_Target_3_GenBank_ID_Gene:
AK222814

# Drug_Target_3_GenBank_ID_Protein:
62897187

# Drug_Target_3_GeneCard_ID:
TARS2

# Drug_Target_3_Gene_Name:
TARS2

# Drug_Target_3_Gene_Sequence:
>2157 bp
ATGGCCCTGTATCAGAGGTGGCGGTGTCTCCGGCTCCAAGGTTTACAGGCTTGCAGGCTA
CACACGGCAGTTGTGTCGACCCCTCCACGCTGGTTGGCAGAGCGGCTTGGCCTTTTTGAG
GAGCTGTGGGCTGCTCAGGTAAAGAGATTAGCAAGCATGGCACAGAAGGAACCCCGGACT
ATTAAGATATCACTTCCTGGAGGCCAGAAAATTGATGCTGTGGCATGGAACACAACCCCC
TACCAACTAGCCCGGCAGATCAGTTCAACACTGGCAGATACTGCAGTGGCTGCTCAAGTG
AATGGAGAACCTTATGATCTGGAGCGGCCCTTGGAGACAGATTCTGACCTCAGATTTCTG
ACATTCGATTCCCCAGAGGGGAAAGCAGTGTTCTGGCACTCCAGCACCCATGTCCTGGGG
GCAGCAGCTGAACAATTCCTAGGTGCTGTTCTCTGCAGAGGTCCAAGTACAGAATATGGC
TTTTACCATGATTTCTTCCTGGGAAAGGAGAGGACAATCCGGGGCTCAGAGCTGCCTGTT
TTGGAGCGGATTTGCCAGGAACTTACAGCTGCTGCTCGACCCTTCCGGAGGCTAGAGGCT
TCACGGGATCAGCTTCGCCAGTTGTTCAAGGATAACCCCTTTAAGCTTCACTTGATTGAG
GAGAAAGTGACAGGTCCAACAGCAACAGTATATGGGTGTGGCACATTGGTTGACCTTTGC
CAGGGCCCCCACCTTCGGCATACTGGACAGATTGGAGGACTGAAGCTGCTATCGAACTCA
TCATCCTTATGGAGGTCTTCAGGGCCCCCAGAGACACTGCAGAGAGTGTCAGGGATTTCC
TTCCCCACAACAGAATTGCTGAGGGTCTGGGAAGCATGGAGGGAGGAAGCAGAATTGCGG
GACCACCGGCGCATTGGGAAGGAACAGGAGCTCTTCTTCTTCCATGAACTGAGCCCTGGG
AGCTGCTTCTTCCTGCCACGAGGGACAAGGGTGTATAATGCACTAGTGGCGTTTATCAGG
GCTGAGTATGCCCATCGTGGTTTCTCCGAGGTGAAAACTCCCACACTGTTTTCTACGAAG
CTCTGGGAACAGTCAGGGCACTGGGAGCATTATCAGGAAGACATGTTTGCCGTGCAGCCC
CCAGGCTCTGACAGGCCTCCCAGCTCCCAGAGTGACGATTCTACCAGGCATATCACAGAT
ACACTCGCCCTCAAGCCTATGAACTGCCCTGCACACTGCCTGATGTTCGCCCACCGGCCC
AGATCCTGGCGGGAACTGCCCCTGCGACTAGCTGACTTTGGGGCTCTACACCGGGCCGAA
GCCTCTGGTGGTCTGGGGGGACTGACCCGACTGCGGTGCTTCCAGCAGGATGACGCTCAC
ATCTTCTGTACAACAGATCAGCTGGAAGCAGAGATCCAAAGCTGTCTTGATTTCCTCCGT
TCCGTCTATGCCGTTCTTGGCTTCTCCTTCCGCCTGGCACTGTCCACCCGGCCATCTGGC
TTCCTGGGGGACCCTTGCCTTTGGGACCAGGCCGAACAGGTCCTTAAACAGGCCCTGAAG
GAATTTGGAGAACCCTGGGACCTCAACTCTGGAGATGGTGCCTTCTATGGACCTAAGATT
GACGTGCACCTCCACGATGCCCTGGGCCGGCCACATCAGTGTGGGACAATTCAGCTTGAC
TTCCAACTGCCCCTGAGATTTGACCTCCAGTATAAGGGGCAGGCGGGTGCCCTGGGGCGT
CCAGTCCTCATTCACCGAGCAGTGCTCGGTTCTGTGGAAAGACTGTTGGGAGTGCTGGCA
GAAAGCTGCGGGGGGAAATGGCCACTGTGGCTGTCCCCGTTCCAGGTGGTGGTCATCCCT
GTGGGGAGTGAGCAAGAGGAATACGCCAAAGAGGCACAGCAGAGCCTGCGGGCTGCAGGA
CTGGTCAGTGACCTGGATGCAGACTCTGGACTGACCCTCAGCCGGAGAATCCGCCGGGCC
CAGCTTGCCCACTACAATTTTCAGTTTGTGGTTGGCCAGAAAGAGCAAAGTAAGAGAACA
GTGAACATTCGGACTCGAGATAATCGTCGCCTTGGGGAGTGGGACTTGCCTGAGGCTGTG
CAGCGACTGGTGGAGCTACAGAACACGAGGGTCCCAAATGCCGAAGAAATTTTCTGA

# Drug_Target_3_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_3_General_References:
Not Available

# Drug_Target_3_HGNC_ID:
HGNC:30740

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4069

# Drug_Target_3_Locus:
1q21.2

# Drug_Target_3_Molecular_Weight:
81037

# Drug_Target_3_Name:
Threonyl-tRNA synthetase, mitochondrial

# Drug_Target_3_Number_of_Residues:
718

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00587	tRNA-synt_2b
PF02824	TGS
PF03129	HGTP_anticodon
PF07973	tRNA_SAD

# Drug_Target_3_Protein_Sequence:
>Threonyl-tRNA synthetase, mitochondrial
MALYQRWRCLRLQGLQACRLHTAVVSTPPRWLAERLGLFEELWAAQVKRLASMAQKEPRT
IKISLPGGQKIDAVAWNTTPYQLARQISSTLADTAVAAQVNGEPYDLERPLETDSDLRFL
TFDSPEGKAVFWHSSTHVLGAAAEQFLGAVLCRGPSTEYGFYHDFFLGKERTIRGSELPV
LERICQELTAAARPFRRLEASRDQLRQLFKDNPFKLHLIEEKVTGPTATVYGCGTLVDLC
QGPHLRHTGQIGGLKLLSNSSSLWRSSGAPETLQRVSGISFPTTELLRVWEAWREEAELR
DHRRIGKEQELFFFHELSPGSCFFLPRGTRVYNALVAFIRAEYAHRGFSEVKTPTLFSTK
LWEQSGHWEHYQEDMFAVQPPGSDRPPSSQSDDSTRHITDTLALKPMNCPAHCLMFAHRP
RSWRELPLRLADFGALHRAEASGGLGGLTRLRCFQQDDAHIFCTTDQLEAEIQSCLDFLR
SVYAVLGFSFRLALSTRPSGFLGDPCLWDQAEQVLKQALKEFGEPWDLNSGDGAFYGPKI
DVHLHDALGRPHQCGTIQLDFQLPLRFDLQYKGQAGALERPVLIHRAVLGSVERLLGVLA
ESCGGKWPLWLSPFQVVVIPVGSEQEEYAKEAQQSLRAAGLVSDLDADSGLTLSRRIRRA
QLAHYNFQFVVGQKEQSKRTVNIRTRDNRRLGEWDLPEAVQRLVELQNTRVPNAEEIF

# Drug_Target_3_Reaction:
ATP + L-threonine + tRNAThr = AMP + diphosphate + L-threonyl-tRNAThr

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
ATP + L-threonine + tRNA(Thr) = AMP + diphosphate + L-threonyl-tRNA(Thr)

# Drug_Target_3_SwissProt_ID:
Q9BW92

# Drug_Target_3_SwissProt_Name:
SYTM_HUMAN

# Drug_Target_3_Synonyms:
EC 6.1.1.3
ThrRS
Threonine--tRNA ligase
Threonyl-tRNA synthetase, mitochondrial precursor
Threonyl-tRNA synthetase-like 1

# Drug_Target_3_Theoretical_pI:
7.31

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00156
